There is a realistic expectation that the global effort in vaccination will bring the pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control …

Patients diagnosed with coronavirus disease 2019 (COVID-19) become critically ill primarily
around the time of activation of the adaptive immune response. Here, we provide evidence …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Abstracts Recent evidence suggests that CD147 serves as a novel receptor for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Blocking CD147 via anti …

Background Hyperimmune immunoglobulin (hIVIG) contains polyclonal antibodies, which
can be prepared from large amounts of pooled convalescent plasma or prepared from …

Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …

Summary Background Afucosylated IgG1 responses have only been found against
membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These …

Background Patients with chronic kidney disease (CKD) or kidney replacement therapy
demonstrate lower antibody levels after severe acute respiratory syndrome coronavirus 2 …